Skip to main content

Health condition · Clinically reviewed

Lung nodules, what a spot on your scan actually means.

Found by chance on a scan done for something else - and most of the time, nothing to worry about. Here’s how the risk is assessed properly.

Jump to management
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against British Thoracic Society and Fleischner Society guidance, referenced at the end.

  • 03

    Current for 2026

    Reflects modern UK practice including volumetric CT surveillance and PET-CT risk stratification.

Key facts

Lung nodules at a glance.

The essentials, in plain English - what a nodule is, why most aren’t serious, and how the risk is actually worked out.

  • What it is

    A small (under 3cm), rounded area of increased density seen on a chest X-ray or CT - almost always found by chance.

  • How common

    Very common - incidental nodules turn up on roughly one in four CT scans of the chest done for other reasons.

  • Usually benign

    The large majority are granulomas, hamartomas or intrapulmonary lymph nodes - not cancer.

  • When risk rises

    Larger size, growth over time, a smoking history and older age all push the probability of malignancy up.

  • Main tool

    CT chest characterisation - solid, part-solid or ground-glass - drives the whole management pathway.

  • Guided by

    British Thoracic Society (BTS) guidelines and the Fleischner Society risk-stratification criteria.

Why this guide matters

A structured pathway, not guesswork.

Being told you have a lung nodule is unsettling, even though most turn out fine. The three points below explain how modern practice keeps that reassurance evidence-based rather than reflexive.

  • Most nodules are benign

    Granulomas, hamartomas and intrapulmonary lymph nodes account for the majority of incidental findings - cancer is the minority explanation.

  • Risk is calculated, not guessed

    Size, morphology, growth rate and patient risk factors feed into validated Fleischner and BTS risk models, not a gut feeling.

  • Surveillance catches change early

    Where a nodule sits between clearly benign and clearly worrying, scheduled CT surveillance is designed to detect growth while it is still easily treatable.

How the assessment is made

From an incidental finding to a clear plan.

The steps a UK respiratory team or radiologist will normally follow, in order - so you know what to expect and why.

  1. 01

    Assessing

    Incidental finding

    Most nodules are spotted on a chest X-ray or CT done for an unrelated reason - you rarely feel anything.

  2. 02

    Assessing

    Risk stratification

    Size, morphology, growth rate and patient factors (age, smoking, family history) are combined into a risk estimate.

  3. 03

    Assessing

    CT chest characterisation

    A dedicated CT defines whether the nodule is solid, part-solid or ground-glass - each behaves differently.

  4. 04

    Confirming

    PET-CT if indeterminate

    For solid nodules over about 8mm with uncertain risk, PET-CT looks at metabolic activity to help separate benign from malignant.

  5. 05

    Confirming

    Volumetric measurement

    Software-based volume measurement plus volume-doubling time is more sensitive than eyeballing diameter on successive scans.

  6. 06

    Deciding

    Selective biopsy

    Reserved for high-risk features - biopsy is not needed for the majority of low-risk nodules.

  7. 07

    Deciding

    MDT review

    Specialist-commissioned respiratory and lung cancer multidisciplinary teams review indeterminate or high-risk cases.

Typical timeline: an initial CT to a settled surveillance plan within a few weeks.

Features

What a lung nodule actually looks like on a scan.

There is almost never anything to feel - it is a radiological appearance, not a symptom. Here is what radiologists are looking for.

  • No symptoms at all

    Almost every nodule is picked up incidentally - there is usually nothing to feel or notice.

  • Solid nodule

    Uniform density throughout - the most common pattern and the one PET-CT works best for.

  • Part-solid nodule

    A mix of solid and hazy components - this pattern carries a higher relative risk of malignancy.

  • Ground-glass nodule

    A faint hazy density that doesn’t obscure underlying lung markings - often grows slowly if it changes at all.

  • Multiple nodules

    More than one nodule raises the question of a metastatic source if a primary cancer is already known.

  • Growth on follow-up

    A nodule that enlarges between scans is the single strongest signal for escalation.

  • Risk-factor cluster

    Older age, a significant smoking history, or a family history of lung cancer shift management toward closer surveillance.

  • Red flag - large or growing solid nodule

    A large, growing, solid or spiculated nodule deserves prompt PET-CT and MDT discussion.

Management

How lung nodules are managed in the UK.

No follow-up for the lowest-risk findings, structured surveillance for the middle ground, and PET-CT, biopsy or surgery for anything higher-risk.

  • No follow-up needed

    Very low risk, small nodules - typically under 6mm and low risk features - often need no further imaging at all.

  • Surveillance CT

    Low-to-moderate risk nodules are rechecked on a defined BTS schedule - commonly at 3, 6, 12 and 24 months.

  • PET-CT

    Used for indeterminate solid nodules above about 8mm to help decide whether biopsy or resection is warranted.

  • Image-guided or bronchoscopic biopsy

    Selective sampling for nodules with high-risk features where a tissue diagnosis will change management.

  • VATS wedge resection

    Minimally invasive surgical removal for high-risk or growing nodules - see our guide to VATS lobectomy.

  • Metastatic workup

    When multiple nodules appear alongside a known primary cancer elsewhere, staging investigations look for spread.

  • Smoking cessation support

    Stopping smoking reduces future risk regardless of what today’s nodule turns out to be.

  • Shared decision-making

    Risk, anxiety and personal preference are weighed together with your respiratory team before choosing a pathway.

When surgery is needed, VATS wedge resection removes the nodule through small keyhole incisions - see our guide to VATS lobectomy for how this is done. A private CT scan can also speed up initial characterisation where NHS waiting times are a concern.

What this guide is based on

The sources behind every claim on this page.

UK national guidance and international specialist society standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your respiratory team knows your scans and your history and can tell you exactly where your nodule sits on the risk scale. If in doubt, get seen.

  • British Thoracic Society (BTS). Guideline for the investigation and management of pulmonary nodules.

  • Fleischner Society. Guidelines for management of incidental pulmonary nodules detected on CT images.

  • NICE. Lung cancer: diagnosis and management (NG122).

  • Roy Castle Lung Cancer Foundation. Patient information on lung nodules and early diagnosis.

Red flags

When a lung nodule needs urgent attention.

Most nodules are managed calmly with scheduled surveillance. These are the situations that call for faster action.

  • Rapid growth on serial imaging

    A nodule with a short volume-doubling time on successive scans needs urgent respiratory review.

  • Spiculated or irregular margins

    An irregular, spiculated edge is a recognised high-risk morphological feature warranting prompt assessment.

  • Large solid nodule (over 2cm)

    Larger solid nodules carry substantially higher malignancy risk and are usually fast-tracked for PET-CT.

  • New or worsening breathlessness

    Symptoms alongside a known nodule should never be dismissed as unrelated - report them promptly.

  • Unexplained weight loss or haemoptysis

    Coughing blood or losing weight without explanation are classic red flags that need urgent same-pathway assessment.

  • Multiple nodules with a known cancer

    Suggests possible metastatic spread and needs staging investigation without delay.

  • Strong smoking history plus growth

    Growth in a nodule found in a heavy or long-term smoker carries a materially higher pre-test probability of malignancy.

  • Missed or delayed follow-up scan

    Surveillance only works if scans happen on schedule - a missed appointment should be rebooked as a priority, not skipped.

  • New nodule after previous cancer

    Any new nodule in someone with a history of cancer elsewhere warrants specific discussion with the MDT.

Living with it

A manageable finding, with a clear pathway.

Four things that make the biggest difference while a nodule is being watched - realistic perspective, attending every scan, cutting your own risk, and understanding where you sit.

A quiet reminder

Watchful waiting is an active plan, not inaction.

Scheduled surveillance is a deliberate, evidence-based strategy - not a wait-and-see shrug.

  1. 01 Perspective

    Most nodules are nothing sinister

    The great majority of incidental nodules turn out to be old infection, scarring or a harmless lymph node.

  2. 02 Attend

    Keep every surveillance appointment

    The BTS schedule exists because change over time - not a single snapshot - is what separates benign from malignant.

  3. 03 Reduce risk

    Stop smoking if you smoke

    Quitting lowers the risk attached to any nodule and reduces the chance of a new one appearing.

  4. 04 Ask questions

    Understand your own risk category

    Ask your team where your nodule sits on the Fleischner or BTS risk scale, and what would change the plan.

Frequently asked

Everything we get asked about lung nodules.

Quick answers on risk, surveillance, PET-CT and when biopsy or surgery come into the picture.

  • What is a lung nodule?

    A small, rounded area of tissue on a chest X-ray or CT, typically under 3cm across. It is a description of an appearance on a scan, not a diagnosis in itself - most are found incidentally while imaging is done for another reason.

  • Does a lung nodule mean I have cancer?

    No - the great majority of nodules are benign, caused by things like old infection (granulomas), hamartomas or intrapulmonary lymph nodes. Risk of malignancy rises with size, growth on follow-up scans, and a significant smoking history.

  • Will I need a biopsy?

    Usually not. Biopsy is reserved for nodules with high-risk features on CT or PET-CT where a tissue diagnosis would change the plan. Most low and moderate-risk nodules are simply monitored with follow-up scans.

  • What does surveillance CT actually involve?

    Repeat CT scans at set intervals, commonly 3, 6, 12 and 24 months under BTS guidance, with volumetric measurement to track any change in size precisely - far more sensitive than comparing diameters by eye.

  • What is PET-CT used for?

    It looks at how metabolically active a nodule is, which helps distinguish benign from malignant when a solid nodule over about 8mm is otherwise indeterminate. It is not needed for every nodule.

  • What happens if my nodule grows?

    Growth is the strongest single trigger for escalation. Depending on size, position and your overall risk, that usually means PET-CT, discussion at a specialist lung cancer multidisciplinary team meeting, and often biopsy or VATS wedge resection.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.